Clinical Trials Logo

SOX clinical trials

View clinical trials related to SOX.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05122091 Recruiting - Gastric Cancer Clinical Trials

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

For locally advanced gastric/gastroesophageal junction adenocarcinoma (cT3/4aN+M0 ), neoadjuvant therapy can downstage T and N stage, improve R0 resection rate, reduce recurrence and metastasis rates, and finally improve the long-term survival. A combination of Fruquintinib and SOX for locally advanced gastric/gastroesophageal junction adenocarcinoma could be a novel therapy. This study intends to evaluate the efficacy of Fruquintinib plus SOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma.